Cormorant Asset Management ELDN Position
ExitedCormorant Asset Management exited their position in Eledon Pharmaceuticals, Inc. (ELDN) in Q2 2023, after holding the stock for 2 quarters.
The position was first reported in Q1 2023 and has been tracked across 2 quarterly 13F filings.
2 other tracked funds also hold ELDN.
Short interest stands at 12.1% of float with 7.7 days to cover, indicating significant bearish positioning against the stock.
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Full company profile →Short Interest
12.1%
7.7 days to cover
Cormorant Asset Management ELDN Position History
Frequently Asked Questions
Does Cormorant Asset Management own ELDN?
No. Cormorant Asset Management exited their position in Eledon Pharmaceuticals, Inc. (ELDN) in Q2 2023. They previously held the stock for 2 quarters.
How many hedge funds own ELDN?
2 specialist biotech hedge funds currently hold ELDN, including BVF Partners, RA Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Cormorant Asset Management first buy ELDN?
Cormorant Asset Management's position in ELDN was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Cormorant Asset Management's ELDN position increasing or decreasing?
Cormorant Asset Management completely exited their ELDN position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ELDNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Cormorant Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →